Key Highlights
- Daniel Lochner appointed as Chief Financial Officer.
- Brings 15 years of healthcare equity investing experience.
- Former CFO and Chief Business Officer at Oyster Point Pharma.
- Transition supported by outgoing CFO Christian Cortis.
Source: Business Wire
Notable Quotes
- “Dan is an experienced public-company CFO who will add significant financial expertise to our team. With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team,” — Alise Reicin, MD, President and CEO at Tectonic
- “It is an honor to join the Tectonic team at the beginning of this new chapter. The company is operating at the forefront of scientific innovation with a mission to unlock the therapeutic utility of GPCRs for which biologics offer advantages over small molecule pharmacology,” — Daniel Lochner, Chief Financial Officer at Tectonic Therapeutic
SoHC's Take
Daniel Lochner’s appointment as CFO of Tectonic Therapeutic is a strategic move that bolsters the company’s financial leadership with his robust background in corporate finance and healthcare equity investing. His experience at Oyster Point Pharma and Goldman Sachs positions him well to drive Tectonic’s business strategy and operational execution, especially as the company advances its innovative GPCR-targeted therapeutic pipeline. This leadership change, coupled with the upcoming merger with AVROBIO, marks a pivotal moment for Tectonic as it continues to push the boundaries of scientific innovation in biologics.
